ZhenFund angel project "Livinova" completes tens of millions of yuan in Pre-A funding; self-developed all-atom model Pallatom makes NVIDIA's recommended list

Hangzhou Liwen Biotechnology has raised tens of millions of RMB in a Pre-A funding round led by Jinyu Maowu, with Junke Danmu participating. Zhoudou Capital served as the exclusive financial advisor. The proceeds will accelerate iteration of its full-atom protein design platform Pallatom, expand its commercial pipeline, and recruit global talent. ZhenFund invested in Liwen at the seed round in 2021 and continued to back the company in its angel round, supporting it ever since.

Liwen's proprietary full-atom protein design platform Pallatom is one of the few AI models globally capable of high-performance, full-atom-level precision design. Pallatom has been featured on NVIDIA's official website, listed alongside leading international models such as AlphaFold3 and ESM3.

On the application side, Pallatom has demonstrated significant commercial value. It has successfully designed replacement molecules for antibody purification core components, launching Protein A alternative molecules with both alkali resistance and high affinity. It also became the first in the world to solve the racemic cyclic peptide design problem, accelerating cyclic peptide drug pipeline development.

Lésign® is an intelligent protein design platform integrating co-evolution and physical potential energy, capable of sequence mutation, structural reconstruction, and functional prediction — forming a closed loop from modeling to experimental validation. Leveraging Lésign®, Liwen has achieved large-scale development and optimization of multiple protein classes, significantly improving R&D efficiency and stability while shortening development cycles from the traditional multi-year timeline to months.

Thanks to the synergistic effect of these two technology platforms, Liwen has built a full-chain system spanning molecular design to process development. The company has already commercialized multiple product lines, including the natural sweetener rebaudioside M, the protein sweetener brazzein, the natural antifreeze protein, and high-performance antibody tool enzymes IdeZ, IdeS, PNGase F, and sialidase — covering pharmaceuticals, synthetic biology, food, animal nutrition, environmental protection, and functional skincare.

This funding round represents capital market recognition of Liwen's technical moat and commercial potential. The company will continue advancing its full-atom protein design capabilities and accelerating the translation of model technology into industrial applications.

Liwen believes that AI-driven protein R&D is reshaping the innovation efficiency of life sciences. Going forward, the company will adopt a more open posture to connect with upstream and downstream industry players, jointly building an innovation loop from foundational models to applied products — accelerating the emergence of new molecules, new materials, and new drugs, and translating technology into genuine industrial value to bring faster, more economical, and more efficient R&D methods to life sciences.

Xiaohongshu｜Lexiang Technology Moonshot AI｜Hero Games｜Biansai Technology

RightBrain Technology｜Hanwei Technology｜UZIS

Heliospace｜Yahaha｜SmartMore Perfect Diary｜Jingying Technology｜Hesai Technology

Youibot｜Zero Zero Robotics｜Yiwu Technology Angry Miao｜KnowYourself｜LiuXing Technology Aurora Epoch｜Black Lake Technology｜Yuangu

Yuguang Technology｜StarCradle｜Qingyue Technology CellX｜Yunzhou Intelligence｜Guna Technology Dingmao Technology｜Weiming Shiguang｜Xellaris